Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968073 | 0.88 | MME (0.59) | MMELTA4HMEN1KMT2AMMP1 | |
| SCHEMBL3368130 | 0.88 | ALDH1A1 (0.43) | MMEMEN1KMT2APSMB5PSMB2 | |
| SCHEMBL25259821 | 0.81 | PSMB1 (0.49) | MMEPSMB5PSMB2MMP1MMP3 | |
| SCHEMBL30450002 | 0.81 | PSMB1 (0.49) | MMEPSMB5PSMB2MMP1MMP3 | |
| SCHEMBL6465336 | 0.81 | PSMB1 (0.49) | MMEPSMB5PSMB2MMP1MMP3 | |
| SCHEMBL5125668 | 0.79 | CTSK (0.64) | PSMB5PSMB2PSMB1CTSL | |
| Carbamic Acid SCHEMBL30450803 | 0.78 | CAPN1 (0.48) | MMEPSMB5PSMB2MMP1MMP3 | |
| SCHEMBL20741006 | 0.77 | CTSK (0.48) | MMEMMP1MMP3ALDH1A1ANPEP | |
| SCHEMBL20741008 | 0.77 | CTSK (0.48) | MMEMMP1MMP3ALDH1A1ANPEP | |
| SCHEMBL5712419 | 0.74 | CAPN1 (0.54) | MEN1KMT2APSMB5PSMB2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998938-B2 | Cancer treatment by combined inhibition of proteasome and telomerase activities | GERON CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010064-A1 | Cancer treatment by combined inhibition of proteasome and telomerase activities | GERON CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1876893-A2 | CANCER TREATMENT BY COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES | Geron Corporation (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006113470-A2 | CANCER TREATMENT BY COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES | GERON CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2003012131-A2 | ASSAYS FOR PROTEASE INHIBITORS, METHODS AND MEANS | USTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED CESKÉ REPUBLIKY (CZ) | 2003-02-13 | — | — | WO | disclosed |
| WO-2001081427-A1 | A REPORTER PROTEIN CONSTRUCT, PARTLY COMPRISING GPF | KAROLINSKA INNOVATIONS AB (SE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010064-A1 | Cancer treatment by combined inhibition of proteasome and telomerase activities | PSMA6, PSME1, PSMB1 | MME 220/4885LTA4H 2391/4885MEN1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.